VBIVQ — VBI Vaccines Balance Sheet
0.000.00%
- $0.01m
- $36.16m
- $8.68m
Annual balance sheet for VBI Vaccines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 44.2 | 119 | 122 | 62.6 | 23.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.201 | 0.077 | 1.45 | 4.13 | 1.27 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 47 | 132 | 130 | 77.7 | 36.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11.7 | 12.3 | 14.4 | 15.6 | 11.9 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 122 | 209 | 210 | 155 | 87 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29.8 | 17.3 | 32.6 | 36.9 | 75.7 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 33.9 | 37.7 | 66.4 | 90.9 | 79.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 88.3 | 172 | 144 | 64.2 | 7.53 |
| Total Liabilities & Shareholders' Equity | 122 | 209 | 210 | 155 | 87 |
| Total Common Shares Outstanding |